PulseAugur / Brief
EN
LIVE 13:50:04

Brief

last 24h
[2/2] 224 sources

Multi-source AI news clustered, deduplicated, and scored 0–100 across authority, cluster strength, headline signal, and time decay.

  1. TOOL · 36氪 (36Kr) 中文(ZH) ·

    Huiyu Pharmaceutical: Clinical Trial Application for Injectable HY07121 (Subcutaneous Injection) Accepted

    Huayu Pharmaceutical's subsidiary, Huayu Haiyue, has received approval from China's National Medical Products Administration to begin clinical trials for HY07121, a novel subcutaneous injection for advanced solid tumors. This innovative biologic is a triple-target fusion protein designed to combat PD-1, TIGIT, and IL-15/IL-15Rα, aiming to enhance patient convenience and reduce side effects. Currently, no other triple-target products are available on the market. AI

    IMPACT This development signifies progress in targeted cancer therapies, potentially offering new treatment options with improved patient outcomes.

  2. COMMENTARY · LessWrong (AI tag) English(EN) ·

    The ballad of TIGIT

    The article discusses TIGIT drugs, a class of cancer immunotherapies that have largely failed to deliver on their initial promise. Similar to the disappointing amyloid-beta drugs for Alzheimer's, TIGIT drugs were developed in the wake of the immense success of Keytruda, another immunotherapy. Despite significant investment and hope, TIGIT drugs have not shown clinically meaningful effects, leading to their current status as a cautionary tale in pharmaceutical research. AI

    The ballad of TIGIT